InnoPharma, Inc. announced the launch of acamprosate calcium, 333 mg delayed-release tablets (generic equivalent of Campral(R)). InnoPharma developed the generic formulation of acamprosate delayed-release tablets and entered into an agreement with Glenmark Pharmaceuticals, Inc. pursuant to which Glenmark will sell, market and distribute acamprosate in the United States. Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.1 TWD | +20.89% | +19.00% | +9.77% |
Apr. 19 | InnoPharmax Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | InnoPharmax Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+9.77% | 46.15M | |
+15.37% | 41.97B | |
+22.56% | 22.34B | |
+14.89% | 15.25B | |
+16.53% | 14B | |
+49.78% | 12.06B | |
-10.77% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- 4172 Stock
- News InnoPharmax Inc.
- InnoPharma, Inc. Announces Commercial Launch of Acamprosate Delayed-Release Tablets in the United States